The forecast for systemic hormonal preparations sales (excluding sex hormones and insulins) in Canada shows a constant value of 1.8% of total sales from 2024 to 2028. This indicates a stabilization without any year-on-year percentage variation. Data for 2023 showed the same sales percentage, illustrating no growth over the past two years.
Looking forward, noteworthy trends include potential advancements in hormone therapy, increasing health awareness, and potential regulatory changes. Monitoring these factors may influence future sales trends but current forecasts suggest stability without immediate growth prospects.
